FdaApplication
NDA 210491
Identifiers
- fda_app_no: NDA210491
Properties
| Property | Value |
|---|---|
| applicant_name | VERTEX PHARMACEUTICALS INC |
| application_type | NDA |
| approval_date | 2018-02-12 |
Revenue by product
SYMDEKO (COPACKAGED)
| Period | Revenue |
|---|---|
| Q4 2023 | $27.8M* |
| Q3 2023 | $33.4M* |
| Q4 2022 | $34.3M* |
| Q3 2022 | $38.2M* |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| SYMDEKO (COPACKAGED) | IVACAFTOR; IVACAFTOR, TEZACAFTOR | 150MG;150MG, 100MG | TABLET;ORAL |
| SYMDEKO (COPACKAGED) | IVACAFTOR; IVACAFTOR, TEZACAFTOR | 75MG;75MG, 50MG | TABLET;ORAL |
2 products